« Return to News | Awards & Advancement

Vantia Therapeutics raises $6.5 million

Wednesday, July 6, 2011 01:13 PM

Pharmaceutical company Vantia Therapeutics has raised $6.5 million in a series B round. The round was co-led by Novo and SV Life Sciences, and included MVM Life Science Partners.

The funding will advance development of Vantia's two clinical candidates, VA106483 for nocturia and VA111913 for dysmenorrhoea, both of which are in phase II trials.

An exploratory phase II trial of VA111913 in the treatment of dysmenorrhoea (painful periods) showed promising evidence of reduced pain levels in patients. VA111913 was well tolerated and significant differences between VA111913 treatment and placebo were seen for a number of efficacy endpoints. The study identified a target population that derived a substantial reduction in period pain fromVA111913 treatment.

VA106483 is being investigated as a new treatment for nocturia in a 30-patient clinical trial to evaluate the dose-response in men aged over 65 years with benign prostatic hypertrophy (BPH). The results are expected in the second half of 2011. Data from previous trials demonstrated a dose-dependent pharmacological effect and suggested VA106483 has potential to be an effective and well-tolerated antidiuretic for the treatment of nocturia.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.